A detailed history of Brown Advisory Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Brown Advisory Inc holds 19,961 shares of AMLX stock, worth $99,006. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,961
Previous 19,961 -0.0%
Holding current value
$99,006
Previous $56,000 33.93%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

BUY
$2.71 - $19.57 $17,615 - $127,205
6,500 Added 48.29%
19,961 $56,000
Q2 2023

Jul 31, 2023

SELL
$20.98 - $31.42 $104,900 - $157,100
-5,000 Reduced 27.08%
13,461 $290,000
Q1 2023

May 08, 2023

SELL
$27.71 - $40.93 $415,095 - $613,131
-14,980 Reduced 44.8%
18,461 $541,000
Q4 2022

Feb 13, 2023

SELL
$29.75 - $39.26 $297,500 - $392,600
-10,000 Reduced 23.02%
33,441 $1.24 Million
Q3 2022

Nov 14, 2022

BUY
$17.15 - $30.92 $745,013 - $1.34 Million
43,441 New
43,441 $1.22 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $290M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Brown Advisory Inc Portfolio

Follow Brown Advisory Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brown Advisory Inc with notifications on news.